Cost-effectiveness of azacitidine compared with low-doses of chemotherapy (LDC) in myelodysplastic syndrome (MDS)

Cost-effectiveness of azacitidine compared with low-doses of chemotherapy (LDC) in myelodysplastic syndrome (MDS)

ABSTRACTIntroductionMyelodysplastic syndrome (MDS) comprises a group of clonal hematological disorders, characterized by ineffective hematopoiesis and progressive bone marrow failure. It increases the risk of transformation to acute myeloid leukemia (AML). Therapeutic benefit should include overall...

Full description

Bibliographic Details
Main Authors: Myrna Candelaria-Hernández, Xavier López Karpovitch, Francisco Javier Mijangos, Efreen Montaño, Arely Lemus Carmona, Silvia Guzmán Vázquez, Herman Soto Molina
Format: Article
Language:English
Published: AboutScience Srl 2017-06-01
Series:Global & Regional Health Technology Assessment
Online Access:http://www.grhta.com/Attach/E91F9375-A784-4DBF-B83B-CCF9F8DA53F1/B75EDBAF-943E-4326-876A-50E445D43272

Internet

http://www.grhta.com/Attach/E91F9375-A784-4DBF-B83B-CCF9F8DA53F1/B75EDBAF-943E-4326-876A-50E445D43272

Similar Items